Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 13/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 12/20 | 0.49 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.46 |
| ▸ | KCNQ4 | P56696 | 1/20 | 0.45 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 5/20 | 0.42 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL826795 | 1.00 | HDAC1 (0.50) | HDAC1HDAC2AAK1KCNQ4KCNQ5 | |
| SCHEMBL29581478 | 0.88 | HDAC1 (0.55) | HDAC1HDAC2AAK1KCNQ4KCNQ5 | |
| SCHEMBL197145 | 0.88 | HDAC1 (0.55) | HDAC1HDAC2AAK1KCNQ4KCNQ5 | |
| SCHEMBL30926421 | 0.87 | HDAC2 (0.42) | HDAC1HDAC2AAK1KCNQ4KCNQ5 | |
| SCHEMBL3407965 | 0.84 | HPGD (0.49) | HDAC1HDAC2AAK1HDAC3 | |
| SCHEMBL29741562 | 0.84 | HPGD (0.49) | HDAC1HDAC2AAK1HDAC3 | |
| SCHEMBL15614546 | 0.84 | MAPT (0.51) | KCNQ4KCNQ5CYP17A1RXFP1 | |
| SCHEMBL2227781 | 0.84 | AAK1 (0.48) | HDAC1HDAC2AAK1HDAC3RXFP1 | |
| SCHEMBL20057682 | 0.83 | AAK1 (0.47) | HDAC1HDAC2AAK1HDAC3RXFP1 | |
| SCHEMBL27398698 | 0.83 | MAPT (0.51) | KCNQ4KCNQ5RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4631931-A1 | HDAC INHIBITOR AND USE THEREOF | Wigen Biomedicine Technology (Shanghai) Co., Ltd. (CN) | 2025-10-15 | — | — | EP | disclosed |
| US-12365664-B2 | Small molecule inhibitors of SRC tyrosine kinase | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-07-22 | — | — | US | disclosed |
| WO-2025041160-A1 | BIFUNCTIONAL CONJUGATE MOLECULES FOR CANCER TREATMENT AND PROCESS OF MAKING THE SAME | BIRLA INSTITUTE OF TECHNOLOGY AND SCIENCE (BITS), PILANI (IN) | 2025-02-27 | — | — | WO | disclosed |
| EP-4093730-B1 | HDAC DEGRADER | UNIV LEICESTER (GB) | 2024-05-08 | — | — | EP | disclosed |
| US-20230120211-A1 | HDAC Degrader | UNIVERSITY OF LEICESTER (GB) | 2023-04-20 | — | — | US | disclosed |
| EP-4093730-A1 | HDAC DEGRADER | University of Leicester (GB) | 2022-11-30 | — | — | EP | disclosed |
| US-20220267294-A1 | SMALL MOLECULE INHIBITORS OF SRC TYROSINE KINASE | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2022-08-25 | — | — | US | disclosed |
| EP-3986411-A1 | SMALL MOLECULE INHIBITORS OF SRC TYROSINE KINASE | Dana-Farber Cancer Institute, Inc. (US) | 2022-04-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12365664-B2 | Small molecule inhibitors of SRC tyrosine kinase | SRC, CTTN, LCK | HDAC1 594/4885HDAC2 1033/4885AAK1 890/4885 |
| US-20230120211-A1 | HDAC Degrader | HDAC1, HDAC11, HDAC3 | HDAC1 1/4885HDAC2 4/4885AAK1 3875/4885 |
| US-20220267294-A1 | SMALL MOLECULE INHIBITORS OF SRC TYROSINE KINASE | SRC, CTTN, LCK | HDAC1 594/4885HDAC2 1033/4885AAK1 890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.